{
    "clinical_study": {
        "@rank": "70380", 
        "arm_group": [
            {
                "arm_group_label": "Remifentanil", 
                "arm_group_type": "Active Comparator", 
                "description": "Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.\nStart dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
            }, 
            {
                "arm_group_label": "Propofol", 
                "arm_group_type": "Active Comparator", 
                "description": "Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.\nStart dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to compare remifentanil and propofol for sedation of patients\n      during endoscopic gastrointestinal procedures."
        }, 
        "brief_title": "Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures", 
        "completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "detailed_description": {
            "textblock": "The administration of sedation with target controlled infusion (TCI) systems could offer a\n      safe alternative for the management of discomfort of patients undergoing endoscopic\n      gastrointestinal procedures. However, what medication from those available for TCI would be\n      the most appropriate is not known.\n\n      Sixty-nine patients requiring a gastrointestinal endoscopic procedure were randomly assigned\n      to receive a TCI effect site (e) of remifentanil (n=30) or propofol (n=39). The primary\n      outcome was patient satisfaction. Secondary outcomes included gastroenterologist\n      satisfaction, the proportion of adverse events between the two groups were compared\n      (occurrence of cardiac arrhythmias, mild respiratory depression, major respiratory\n      depression, bradycardia, hypotension, pain, nausea or vomiting, and lack of amnesia), and\n      the level of consciousness."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient undergoing elective higher, lower or mixed gastrointestinal endoscopy at\n             Hospital de San Jose, Bogota, between January and December 2010.\n\n          -  Be between 18 and 70 years old.\n\n          -  American Society of Anesthesiology Physical Status classification between 1 and 3.\n\n          -  Provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients with difficult airway indicators.\n\n          -  Pregnant women.\n\n          -  Patients with chronic pain.\n\n          -  Chronic opioid or benzodiazepine users (>3 months).\n\n          -  Allergy history to remifentanil or propofol or eggs.\n\n          -  Psychoactive drug users.\n\n          -  Smokers (> 5 cigarettes per day in the previous 3 months).\n\n          -  Body mass index > 30."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746641", 
            "org_study_id": "Acta No. 197"
        }, 
        "intervention": [
            {
                "arm_group_label": "Remifentanil", 
                "intervention_name": "Remifentanil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Propofol", 
                "intervention_name": "Propofol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Propofol", 
                "Remifentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Remifentanil", 
            "Propofol", 
            "Sedation", 
            "Endoscopy", 
            "Gastroenterology", 
            "Target controlled infusion effect site"
        ], 
        "lastchanged_date": "December 8, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bogota", 
                    "country": "Colombia", 
                    "zip": "11001000"
                }, 
                "name": "Fundaci\u00f3n Universitaria de Ciencias de la Salud"
            }
        }, 
        "location_countries": {
            "country": "Colombia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Remifentanil Versus Propofol With Target Controlled Infusion Effect Site for the Sedation of Patients During Gastrointestinal Endoscopic Procedures: Randomized Controlled Trial", 
        "other_outcome": {
            "description": "Ramsay scale.", 
            "measure": "Level of consciousness", 
            "safety_issue": "No", 
            "time_frame": "Every minute until the end of the procedure, expected average of 30 minutes"
        }, 
        "overall_official": [
            {
                "affiliation": "Fundacion Universitaria de Ciencias de la Salud", 
                "last_name": "Luis A Mu\u00f1oz, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Fundacion Universitaria de Ciencias de la Salud", 
                "last_name": "Luis E Reyes, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Colombia: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Measured with a analog scale from 1 to 4:\nExcellent.\nGood.\nRegular.\nNo.", 
            "measure": "Patient satisfaction", 
            "safety_issue": "No", 
            "time_frame": "At the end of the procedure, expected average of 30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746641"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured with a analog scale from 1 to 4:\nExcellent.\nGood.\nRegular.\nNo.", 
                "measure": "Gastroenterologist satisfaction", 
                "safety_issue": "No", 
                "time_frame": "At the end of the procedure, expected average of 30 minutes"
            }, 
            {
                "description": "Occurrence of cardiac arrythmias, mild respiratory depression, severe respiratory depression, bradycardia, hypotension, pain, nausea or vomiting, absence of amnesia.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "At the end of the procedure, expected average of 30 minutes"
            }
        ], 
        "source": "Fundaci\u00f3n Universitaria de Ciencias de la Salud", 
        "sponsors": {
            "collaborator": {
                "agency": "Hospital de San Jose", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n Universitaria de Ciencias de la Salud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2012", 
        "why_stopped": "Occurrence of severe respiratory depression in the remifentanil group."
    }
}